Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

121. Universal Internet-based prevention for alcohol and cannabis use reduces truancy, psychological distress and moral disengagement: A cluster randomised controlled trial (Abstract)

Universal Internet-based prevention for alcohol and cannabis use reduces truancy, psychological distress and moral disengagement: A cluster randomised controlled trial A universal Internet-based preventive intervention has been shown to reduce alcohol and cannabis use. The aim of this study was to examine if this program could also reduce risk-factors associated with substance use in adolescents.A cluster randomised controlled trial was conducted in Sydney, Australia in 2007-2008 to assess (...) the effectiveness of the Internet-based Climate Schools: Alcohol and Cannabis course. The evidence-based course, aimed at reducing alcohol and cannabis use, consists of two sets of six lessons delivered approximately six months apart. A total of 764 students (mean 13.1years) from 10 secondary schools were randomly allocated to receive the preventive intervention (n=397, five schools), or their usual health classes (n=367, five schools) over the year. Participants were assessed at baseline, immediately post

2014 EvidenceUpdates Controlled trial quality: uncertain

122. Problems With the Medicalization of Marijuana Full Text available with Trip Pro

Problems With the Medicalization of Marijuana 24845238 2014 06 23 2018 12 07 1538-3598 311 23 2014 Jun 18 JAMA JAMA Problems with the medicalization of marijuana. 2377-8 10.1001/jama.2014.6175 Wilkinson Samuel T ST Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut. D'Souza Deepak Cyril DC Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut2Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, Connecticut3Schizophrenia (...) and Neuropharmacology Research Group, VA Connecticut Healthcare System. eng L30 MH111000 MH NIMH NIH HHS United States R25 MH071584 MH NIMH NIH HHS United States Journal Article United States JAMA 7501160 0098-7484 0 Medical Marijuana AIM IM JAMA. 2014 Nov 12;312(18):1931-2 25387198 JAMA. 2014 Nov 12;312(18):1931 25387197 Drug Approval Evidence-Based Medicine Humans Medical Marijuana therapeutic use Physician's Role Practice Patterns, Physicians' State Government United States United States Food and Drug

2014 JAMA

123. Big Marijuana - Lessons from Big Tobacco. Full Text available with Trip Pro

, Boston Children's Hospital, and Harvard Medical School - both in Boston (S.L.). Levy Sharon S eng Historical Article Journal Article 2014 06 11 United States N Engl J Med 0255562 0028-4793 0 Medical Marijuana AIM IM Adolescent Adult Cannabis Consumer Product Safety Government Regulation History, 19th Century History, 20th Century Humans Industry legislation & jurisprudence Marijuana Smoking adverse effects legislation & jurisprudence Marketing Medical Marijuana Smoking adverse effects history Tobacco (...) Big Marijuana - Lessons from Big Tobacco. 24918955 2014 08 12 2014 07 31 1533-4406 371 5 2014 Jul 31 The New England journal of medicine N. Engl. J. Med. Big marijuana--lessons from big tobacco. 399-401 10.1056/NEJMp1406074 Richter Kimber P KP From the Department of Preventive Medicine and Public Health, University of Kansas Medical Center, and the University of Kansas Cancer Center - both in Kansas City (K.P.R.); and the Division of Developmental Medicine and Adolescent Substance Abuse Program

2014 NEJM

124. The use of medical marijuana: guidelines and recommendations

The use of medical marijuana: guidelines and recommendations The use of medical marijuana: guidelines and recommendations The use of medical marijuana: guidelines and recommendations CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. The use of medical marijuana: guidelines and recommendations. Ottawa: Canadian Agency for Drugs (...) and Technologies in Health (CADTH). Rapid Response - Reference List. 2013 Authors' conclusions No relevant evidence-based guidelines regarding the use of medical marijuana for specific medical conditions were identified. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Medical Marijuanas Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs

2014 Health Technology Assessment (HTA) Database.

125. Efficacy and safety of medical marijuana in selected neurologic disorders

; NRS = numeric rating score ; OCE = oral cannabis extract ; THC = Δ-9-tetrahydrocannabinol ; UHDRS = Unified Huntington's Disease Rating Scale ; UPDRS = Unified Parkinson's Disease Rating Scale ; VAS = visual analog scale Marijuana contains approximately 60 pharmacologically active compounds (“cannabinoids”). Δ-9-Tetrahydrocannabinol (THC) was isolated in 1964 and the nonpsychoactive cannabidiol (CBD) in 1963; the ratio in botanical and pharmaceutical preparations determines therapeutic vs (...) and the ratio of THC to CBD, which limits THC's psychoactive effects, play a role in therapeutic effects of cannabis products. presents the cannabinoid formulations examined here. A variety of formulations was used, with differing amounts of THC and CBD: some were pills, one was a mucosal spray, and some were vaporized or smoked. View this table: Table 1 Cannabinoid formulations This evidence-based systematic review seeks to answer questions regarding safety and efficacy of cannabinoids in relieving

2014 American Academy of Neurology

126. Timothy grass standardized allergenic extract (Grastek ? Merck Canada Inc.) indication: allergic rhinitis (grass pollen)

Timothy grass standardized allergenic extract (Grastek ? Merck Canada Inc.) indication: allergic rhinitis (grass pollen) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen) CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation CADTH. Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen) Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0352. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that Timothy grass (phleum pratense) standardized allergenic extract (PPAE) not be listed. Final publication URL Indexing

2014 Health Technology Assessment (HTA) Database.

127. Medical marijuana for the treatment of mental illness: clinical evidence

: clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One non-randomized study regarding the clinical effectiveness of marijuana for the treatment of adults with mental illness was identified. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cannabis; Humans; Mental Disorders Language Published English Country of organisation Canada Province or state Ontario English summary An English language (...) Medical marijuana for the treatment of mental illness: clinical evidence Medical marijuana for the treatment of mental illness: clinical evidence Medical marijuana for the treatment of mental illness: clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Medical marijuana for the treatment of mental illness

2014 Health Technology Assessment (HTA) Database.

128. Not for Human Consumption: Cannabinoid Receptor Agonists As An Emerging Drug Of Abuse

Not for Human Consumption: Cannabinoid Receptor Agonists As An Emerging Drug Of Abuse Not for Human Consumption: Cannabinoid Receptor Agonists As An Emerging Drug Of Abuse – Clinical Correlations Search Not for Human Consumption: Cannabinoid Receptor Agonists As An Emerging Drug Of Abuse July 26, 2013 7 min read By Ryland Pace Faculty Peer Reviewed Cannabinoid receptor agonists (CRAs) have been recently popularized as “legal” alternatives to marijuana and are becoming increasingly common (...) , Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011;6(7):e21719. 9. Seely KA, Brents LK, Radominska-Pandya A, et al. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012:25(4):825-827. 10. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11(1

2013 Clinical Correlations

129. Grass pollen extract (Oralair®) for allergic rhinitis. Expensive long-term preventive treatment of modest efficacy

Grass pollen extract (Oralair®) for allergic rhinitis. Expensive long-term preventive treatment of modest efficacy 2013. DAR No 3. Grass pollen extract (Oralair®) for allergic rhinitis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 3. Grass pollen extract (Oralair®) for allergic rhinitis DAR No 3. Grass pollen extract (Oralair®) for allergic rhinitis Content tools Share it An expensive, long-term preventive treatment of modest (...) efficacy An allergen extract of five grass pollens is indicated for the management of allergic rhinitis caused by grass pollen with clinically relevant symptoms and diagnosed with specific tests. The allergenic extract has shown modest efficacy in trials compared to placebo. There are no comparative trials with other immunotherapies. A high percentage of patients included in the trials suffered local adverse reactions, especially children, of which the most frequent was oral pruritus (32%). Although

2013 Drug and Therapeutics Bulletin of Navarre (Spain)

130. Grass Pollen Allergen Extract - Allergic rhinitis

Grass Pollen Allergen Extract - Allergic rhinitis Common Drug Review CDEC Meeting – February 20, 2013 Notice of CDEC Final Recommendation – March 20, 2013 Page 1 of 5 © 2013 CADTH FINAL CDEC RECOMMENDATION GRASS POLLEN ALLERGEN EXTRACT (Oralair – Paladin Labs Inc.) Indication: Allergic Rhinitis (Grass Pollen) Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that 5-grass pollen allergen extract (5-GPAE) be listed for the seasonal treatment of grass pollen allergic rhinitis (...) : The Committee noted that for the Common Drug Review (CDR) participating drug plans that currently fund treatment with SCIT for allergic rhinitis, 5-GPAE could be listed in a manner similar to SCIT, provided the cost of treatment with 5-GPAE does not exceed that of SCIT. Background: 5-GPAE has a Health Canada indication for the treatment of symptoms of moderate to severe seasonal grass pollen allergic rhinitis with or without conjunctivitis in patients five to 50 years of age, confirmed by clinically

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

131. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. (Abstract)

participants were randomised by centre, could not be assessed.Despite dronabinol being registered by at least some medicines regulatory authorities for the treatment of AIDS-associated anorexia, and some jurisdictions making allowances for the "medical" use of marijuana by patients with HIV/AIDS, evidence for the efficacy and safety of cannabis and cannabinoids in this setting is lacking. Such studies as have been performed have been of short duration, in small numbers of patients, and have focused (...) The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. The use of cannabis (marijuana) or of its psychoactive ingredient delta-9-tetrahydrocannabinol (THC) as a medicine has been highly contested in many settings.There have been claims that smoked or ingested cannabis, either in its natural form or artificial form (pharmaceutically manufactured drug such as dronabinol), improves the appetites of people with AIDS, results in weight gain and lifts mood, thus

2013 Cochrane

132. Medicinal Use of Marijuana. (Abstract)

Medicinal Use of Marijuana. 23425133 2013 03 07 2013 11 21 1533-4406 368 9 2013 Feb 28 The New England journal of medicine N. Engl. J. Med. Clinical decisions. Medicinal use of marijuana. 866-8 10.1056/NEJMclde1300970 Bostwick J Michael JM Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. Reisfield Gary M GM DuPont Robert L RL eng Case Reports Journal Article 2013 02 20 United States N Engl J Med 0255562 0028-4793 0 Plant Preparations 80168379AG Doxorubicin AIM IM Aged (...) Breast Neoplasms complications drug therapy Cannabis Doxorubicin adverse effects Fatigue drug therapy etiology Female Humans Nausea chemically induced drug therapy Pain drug therapy etiology Phytotherapy Plant Preparations therapeutic use Plants, Medicinal Spinal Neoplasms complications drug therapy secondary 2013 2 22 6 0 2013 2 22 6 0 2013 3 8 6 0 ppublish 23425133 10.1056/NEJMclde1300970

2013 NEJM

133. The Use of Medical Marijuana: Guidelines and Recommendations

Marijuana 3 APPENDIX – FURTHER INFORMATION: Systematic Reviews and Meta-Analysis – Evidence for Use in Various Indications 1. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol [Internet]. 2011 Nov [cited 2013 Jan 10;72(5):735-44. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243008 PubMed: PM21426373 2. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV (...) ://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218077 PubMed: PM20434623 4. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev. 2009;(4):CD006565. PubMed: PM19821373 5. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;(2):CD007204. PubMed: PM19370677 6. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol [Internet]. 2009 [cited 10

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

134. Vulnerability for psychosis at ages 13 and 16 predicts cannabis use at ages 16 and 19, and cannabis use at age 16 predicts psychosis vulnerability at age 19

Vulnerability for psychosis at ages 13 and 16 predicts cannabis use at ages 16 and 19, and cannabis use at age 16 predicts psychosis vulnerability at age 19 Vulnerability for psychosis at ages 13 and 16 predicts cannabis use at ages 16 and 19, and cannabis use at age 16 predicts psychosis vulnerability at age 19 | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vulnerability for psychosis at ages 13 and 16 predicts cannabis use at ages 16

2013 Evidence-Based Mental Health

135. Drugs for multiple sclerosis - Drug Facts box for Cannabis extract (Sativex)

with an Ashworth score = 2 No use of cannabis or cannabinoids in 30 days before trial entry Psychosis or severe psychiatric disorder other than depression Severe cardiovascular disorder including poorly controlled hypertension History of seizures 6 weeks including 2- week baseline Sativex 9.4 (SD 6.4) sprays/day (124) Placebo 14.7 (SD 8.4) sprays/day (65) ? Difference in mean change from baseline between Sativex and placebo in spasticity scores (0-to-10 NRS): 0.52 points (95% CI -1.029 to -0.004 (...) severity: spasm, pain, fatigue, tremor, bladder symptoms, sleep quality (p = ns) Novotna, et al., 2011 5 DB RCT Multicentre (51) 241 randomised ITT ? Power calculation ? Jadad: 3 3-month history of spasticity due to MS Moderately severe spasticity (score = 4 on a 0 to 10 patient-rated NRS) No use of cannabis or cannabinoids in 30 days before trial entry Symptoms of spasticity not due to MS Any patient with a concurrent history of significant psychiatric, renal, hepatic, cardiovascular or convulsive

2013 West Midlands Clinical Support Unit

136. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study (Abstract)

High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study Sublingual allergen-specific immunotherapy is a viable alternative to subcutaneous immunotherapy particularly attractive for use in children.This study investigated efficacy and safety of high-dose sublingual immunotherapy (SLIT) in children allergic to grass pollen in a randomized, double-blind, placebo-controlled trial.After a baseline (...) seasonal observation, 207 children aged 4 to 12 years with grass pollen-allergic rhinitis/rhinoconjunctivitis with/without bronchial asthma (Global Initiative for Asthma I/II) received either high-dose grass pollen SLIT or placebo daily for 1 pre-/co-seasonal period. The primary end point was the change of the area under the curve of the symptom-medication score (SMS) from the baseline season to the first season after start of treatment. Secondary outcomes were well days, responders, immunologic

2012 EvidenceUpdates Controlled trial quality: predicted high

137. Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines

Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation CADTH. Cannabinoids for the treatment of post-traumatic stress disorder: a review of the clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions In this update to a previous report, no new clinical studies or guidelines regarding the use of cannabinoids for the treatment of post-traumatic stress disorder were identified. Final publication URL Indexing

2012 Health Technology Assessment (HTA) Database.

138. [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

[Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Extrakt aus Cannabis Sativa – Nutzenbewertung gemäß § 35a SGB V. [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG Berichte 124. 2012 Final publication URL Indexing

2012 Health Technology Assessment (HTA) Database.

139. Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Guidelines

DA, Smith E, Monahan M, Medvecz A, Hagerty B, Krijger L, et al. Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation. J Am Board Fam Med. 2010 Nov;23(6):790-3. PubMed: PM21057076 13. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010 (...) /September08/BudhrajaArticle.pdf 18. Chepyala P, Olden KW. Cyclic vomiting and compulsive bathing with chronic cannabis abuse. Clin Gastroenterol Hepatol. 2008 Jun;6(6):710-2. PubMed: PM18456571 19. Wallace D, Martin AL, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water. Australas Psychiatry. 2007 Apr;15(2):156-8. PubMed: PM17464661 Review Articles 20. Wallace EA, Andrews SE, Garmany CL, Jelley MJ. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

140. Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines

Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable (...) , provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 27 June 2012 CONTEXT AND POLICY ISSUES In 2009, CADTH reviewed

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review